Which interactions matter in economic evaluations? A systematic review and simulation study

BMC Medical Research Methodology

Alastair Gray¹  Helen Dakin¹ 

[1]Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford

关键词: Factorial randomised controlled trial;    Economic evaluation;    Cost-effectiveness analysis;    Systematic review;    Interactions;    Simulation;   

DOI  :  10.1186/s12874-020-00978-0

来源: DOAJ

【 摘 要 】

Abstract Background We aimed to assess the magnitude of interactions in costs, quality-adjusted life-years (QALYs) and net benefits within a sample of published economic evaluations of factorial randomised controlled trials (RCTs), evaluate the impact that different analytical methods would have had on the results and compare the performance of different criteria for identifying which interactions should be taken into account. Methods We conducted a systematic review of full economic evaluations conducted alongside factorial RCTs and reviewed the methods used in different studies, as well as the incidence, magnitude, statistical significance, and type of interactions observed within the trials. We developed the interaction-effect ratio as a measure of the magnitude of interactions relative to main effects. For those studies reporting sufficient data, we assessed whether changing the form of analysis to ignore or include interactions would have changed the conclusions. We evaluated how well different criteria for identifying which interactions should be taken into account in the analysis would perform in practice, using simulated data generated to match the summary statistics of the studies identified in the review. Results Large interactions for economic endpoints occurred frequently within the 40 studies identified in the review, although interactions rarely changed the conclusions. Conclusions Simulation work demonstrated that in analyses of factorial RCTs, taking account of all interactions or including interactions above a certain size (regardless of statistical significance) minimised the opportunity cost from adopting treatments that do not in fact have the highest true net benefit.

【 授权许可】

Unknown